PHASE Diagnostics 2110400 INDICAID Professional COVID-19 Rap
Medical Professional?
Get [Pro] Pricing
Wish Lists

INDICAID Professional COVID-19 Rapid Antigen Test Box of 25

SKU: MD612211
MFG Part#: 2110400
In Stock

Usually ships in 1 - 3 Days

This product is non returnable
Sale:

$99.00

25 / Kit
was $124.00

Want it shipped today?

Order within: 0 days 14 hours and 15 minutes
Ask an expert
Buy with confidence.
Contact our experts today.

What's In The Box:
  • (25) Lateral Flow Assay Strips
  • (25) Chase Buffer Ampules
  • (25) Vials
  • (25) Locking Caps
  • (25) Individually Wrapped Swabs
  • (1) Instructions for Use
Description

The PHASE Diagnostics INDICAID COVID-19 Rapid Antigen Test is a quick and easy way to test for the presence of SARS-CoV-2, the virus that causes COVID-19. This lateral flow immunoassay is highly accurate, with a sensitivity of 96.52% and a specificity of 99.68%. The test can be performed using a nasopharyngeal swab, making it easy to administer without the need for special training. results are available within 15 minutes, making it one of the fastest antigen tests on the market. This rapid testing solution is ideal for schools, businesses, healthcare facilities, and individuals who want a fast and reliable way to screen for COVID-19

Features
  • Fast: Results in 20 minutes
  • Convenient: No equipment or training needed
  • High Sensitivity: Detect lower viral load samples against competitive products
Show Less Show More
Product Specifications
Sensitivity: 84.4%
Specificity: 97%
Items per Box: 25
Specimen Type: Direct Anterior Nasal Swab
Storage Condition: 36º-86ºF (2º-30ºC) Do not freeze. Avoid direct sunlight.
Shelf Life: 12 Months
See any errors on this page? Let us know
Videos for this product
Frequently Asked Questions (FAQs)
87811 and 87426
The shelf-life of the INDICAID® test is one (1) year from the date of manufacture. The one (1) year expiration date is provided on the label of the outer box.
The swab test method is utilized by the biomedical community for the collection of upper-respiratory specimens for molecular and rapid antigen testing. The CDC supports and promotes this testing method in light of the current COVID-19 pandemic climate for its practicality, simplicity, and efficiency of gathering much-needed data in bulk.
Yes. Insurance, Medicare, and Medicaid cover rapid antigen tests.
Customer Reviews